PD-1/PD-L1-targeting therapies slow down/blockade the “immune escape” of HCC cells (targeting T cells mainly), whereas the SNM could protect immune cells directly and improve the overall immunity of patients. This evidence concerns the gene CD274 and hepatocellular carcinoma.